Literature DB >> 19902523

Definitions of the phenotypic manifestations of sickle cell disease.

Samir K Ballas1, Susan Lieff, Lennette J Benjamin, Carlton D Dampier, Matthew M Heeney, Carolyn Hoppe, Cage S Johnson, Zora R Rogers, Kim Smith-Whitley, Winfred C Wang, Marilyn J Telen.   

Abstract

Sickle cell disease (SCD) is a pleiotropic genetic disorder of hemoglobin that has profound multiorgan effects. The low prevalence of SCD ( approximately 100,000/US) has limited progress in clinical, basic, and translational research. Lack of a large, readily accessible population for clinical studies has contributed to the absence of standard definitions and diagnostic criteria for the numerous complications of SCD and inadequate understanding of SCD pathophysiology. In 2005, the Comprehensive Sickle Cell Centers initiated a project to establish consensus definitions of the most frequently occurring complications. A group of clinicians and scientists with extensive expertise in research and treatment of SCD gathered to identify and categorize the most common complications. From this group, a formal writing team was formed that further reviewed the literature, sought specialist input, and produced definitions in a standard format. This article provides an overview of the process and describes 12 body system categories and the most prevalent or severe complications within these categories. A detailed Appendix provides standardized definitions for all complications identified within each system. This report proposes use of these definitions for studies of SCD complications, so future studies can be comparably robust and treatment efficacy measured. Use of these definitions will support greater accuracy in genotype-phenotype studies, thereby achieving a better understanding of SCD pathophysiology. This should nevertheless be viewed as a dynamic rather than final document; phenotype descriptions should be reevaluated and revised periodically to provide the most current standard definitions as etiologic factors are better understood, and new diagnostic options are developed. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 19902523      PMCID: PMC5046828          DOI: 10.1002/ajh.21550

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  36 in total

1.  Sickle cell-like crisis and bone marrow necrosis associated with parvovirus B19 infection and heterozygosity for haemoglobins S and E.

Authors:  R F Eichhorn; E J Buurke; P Blok; M J Berends; C L Jansen
Journal:  J Intern Med       Date:  1999-01       Impact factor: 8.989

2.  Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes.

Authors:  Laura M De Castro; Jude C Jonassaint; Felicia L Graham; Allison Ashley-Koch; Marilyn J Telen
Journal:  Am J Hematol       Date:  2008-01       Impact factor: 10.047

3.  Sickle cell hepatopathy.

Authors:  T W Sheehy
Journal:  South Med J       Date:  1977-05       Impact factor: 0.954

4.  Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Authors:  Gregory J Kato; Vicki McGowan; Roberto F Machado; Jane A Little; James Taylor; Claudia R Morris; James S Nichols; Xunde Wang; Mirjana Poljakovic; Sidney M Morris; Mark T Gladwin
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

5.  Scintigraphic evidence of pulmonary vascular occlusion in sickle cell disease.

Authors:  R Lisbona; V Derbekyan; J A Novales-Diaz
Journal:  J Nucl Med       Date:  1997-07       Impact factor: 10.057

6.  Pulmonary hypertension in patients with sickle cell disease: a longitudinal study.

Authors:  Kenneth I Ataga; Charity G Moore; Susan Jones; Oludamilola Olajide; Dell Strayhorn; Alan Hinderliter; Eugene P Orringer
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

7.  Long-term management of splenic sequestration in children with sickle cell disease.

Authors:  T R Kinney; R E Ware; W H Schultz; H C Filston
Journal:  J Pediatr       Date:  1990-08       Impact factor: 4.406

Review 8.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

Review 9.  Pulmonary hypertension: an increasingly recognized complication of hereditary hemolytic anemias and HIV infection.

Authors:  Christopher F Barnett; Priscilla Y Hsue; Roberto F Machado
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

Review 10.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Authors:  F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

View more
  108 in total

1.  Responsiveness of the PedsQL to pain-related changes in health-related quality of life in pediatric sickle cell disease.

Authors:  Alyssa M Schlenz; Jeffrey Schatz; Catherine B McClellan; Carla W Roberts
Journal:  J Pediatr Psychol       Date:  2012-03-30

2.  Psychometric Properties of the Psychosocial Assessment Tool-General in Adolescents and Young Adults With Sickle Cell Disease.

Authors:  Lori E Crosby; Naomi E Joffe; Nina Reynolds; James L Peugh; Ellen Manegold; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-08-13

3.  Complications of sickle cell anaemia in children in Northwestern Tanzania.

Authors:  Hamza Saidi; Luke R Smart; Erasmus Kamugisha; Emmanuela E Ambrose; Deogratias Soka; Robert N Peck; Julie Makani
Journal:  Hematology       Date:  2016-02-17       Impact factor: 2.269

4.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

Review 5.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

6.  Hemin Causes Lung Microvascular Endothelial Barrier Dysfunction by Necroptotic Cell Death.

Authors:  Sunit Singla; Justin R Sysol; Benjamin Dille; Nicole Jones; Jiwang Chen; Roberto F Machado
Journal:  Am J Respir Cell Mol Biol       Date:  2017-09       Impact factor: 6.914

Review 7.  cGMP modulation therapeutics for sickle cell disease.

Authors:  Nicola Conran; Lidiane Torres
Journal:  Exp Biol Med (Maywood)       Date:  2019-01-28

8.  A Qualitative Study of Chronic Pain and Self-Management in Adults with Sickle Cell Disease.

Authors:  Nadine Matthie; Diana Ross; Cynthia Sinha; Kirshma Khemani; Nitya Bakshi; Lakshmanan Krishnamurti
Journal:  J Natl Med Assoc       Date:  2018-09-26       Impact factor: 1.798

9.  Development and evaluation of iManage: A self-management app co-designed by adolescents with sickle cell disease.

Authors:  Lori E Crosby; Russell E Ware; Alana Goldstein; Ashley Walton; Naomi E Joffe; Craig Vogel; Maria T Britto
Journal:  Pediatr Blood Cancer       Date:  2016-08-30       Impact factor: 3.167

10.  Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication.

Authors:  Rakhi P Naik; Michael B Streiff; Carlton Haywood; Julie A Nelson; Sophie Lanzkron
Journal:  Am J Med       Date:  2013-05       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.